HIIT and cancer: good adherence in trials, but safety remains poorly documented

People with cancer can take part in intense exercise, but it is not suitable for everyone. A systematic review with meta-analysis reports high adherence to HIIT among enrolled participants. But recruitment remains moderate, and adverse event data are too limited to draw broad conclusions about its safety.

Illustration of interval training on a stationary bike in a cancer care setting.
TrainingEditorial illustration, not study data.

A review focused on feasibility

The researchers brought together 22 studies involving adults with cancer, before, during or after treatment. The groups performing HIIT, or high-intensity interval training, included a total of 559 participants.

The literature search covered three scientific databases through December 31, 2025. The review was registered in PROSPERO and included plans to assess risk of bias and certainty of evidence.

The main question was feasibility: recruitment, adherence and dropout. The available abstract specifies neither the overall duration of the interventions nor the comparators in each study. These findings therefore cannot establish that HIIT is preferable to another form of physical activity.

High adherence after enrollment

The pooled adherence rate was 91%, with a 95% confidence interval ranging from 86 to 95%. The pooled dropout rate was 11%. These estimates come from separate pooled analyses and should not be interpreted as two exactly complementary proportions.

Recruitment was less favorable: its pooled rate was 57%, with a confidence interval of 41 to 72%. The distinction matters: successfully following a program after agreeing to participate does not mean that the program is accessible or acceptable to the entire population concerned.

Recruitment results varied widely across studies. Adherence and dropout showed moderate heterogeneity. No statistically significant differences were observed by treatment phase or exercise setting, but this does not demonstrate equivalence.

The absence of serious events is not enough to establish safety

Only six studies reported adverse event data, with no serious events reported. This finding is encouraging, but such limited reporting cannot rule out risks or support generalization to everyone with cancer.

The useful conclusion therefore remains narrow: HIIT appears feasible for the participants included in these studies. This review demonstrates neither a benefit for cancer itself nor the safety of exercising independently during treatment.

Limitations to keep in mind

Analysis based solely on the supplied PubMed abstract, without consulting the full text. The authors report heterogeneity, risk of bias and limited certainty of evidence. Intervention durations, detailed participant characteristics, funding and conflicts of interest could not be verified.

What we can take away

Good adherence supports the feasibility of HIIT among the participants studied, not a universal recommendation. During cancer care, its potential role should be discussed with the care team.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.